Corvus Pharmaceuticals, Inc. (CRVS): Price and Financial Metrics

Corvus Pharmaceuticals, Inc. (CRVS): $0.86

0.02 (+2.80%)

POWR Rating

Component Grades













Add CRVS to Watchlist
Sign Up

Industry: Biotech



in industry

CRVS Stock Price Chart Interactive Chart >

Price chart for CRVS

CRVS Price/Volume Stats

Current price $0.86 52-week high $2.17
Prev. close $0.84 52-week low $0.70
Day low $0.82 Volume 47,000
Day high $0.87 Avg. volume 110,896
50-day MA $0.87 Dividend yield N/A
200-day MA $0.96 Market Cap 40.22M

Corvus Pharmaceuticals, Inc. (CRVS) Company Bio

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. The company was founded in 2014 and is based in Burlingame, California.

CRVS Latest News Stream

Event/Time News Detail
Loading, please wait...

CRVS Latest Social Stream

Loading social stream, please wait...

View Full CRVS Social Stream

Latest CRVS News From Around the Web

Below are the latest news stories about CORVUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CRVS as an investment opportunity.

4 Penny Stocks Insiders Are Buying: Getaround, Corvus Pharmaceuticals And More

The Dow Jones closed lower by over 700 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. Intellicheck The Trade: Intellicheck, Inc. (NASDAQ: IDN ) President Garrett Gafke bought a total of 2,000 shares at an average price of $2.01. To acquire these shares, it cost around $4.02 thousand. What’s Happening: The company’s stock dipped around 43% over the past six months. What Intelliche...

Benzinga | December 16, 2022

Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Results in patients with refractory T cell lymphoma demonstrated CPI-818’s anti-tumor activity and effects on T cell differentiation which indicate therapeutic potential in Th2 and Th17-mediated autoimmune and allergic diseases Corvus confirms plans to initiate a Phase 2 clinical trial of CPI-818 in T cell lymphoma and a Phase 1 clinical trial in atopic dermatitis, both in 2023 Company to host conference call and webcast today at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif., Dec. 12, 2022 (GLOBE N

Yahoo | December 12, 2022

Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022

Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will host an investor conference call to provide an update on CPI-818 data that will be presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, along with an update

Yahoo | December 5, 2022

James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology

BURLINGAME, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- James T. Rosenbaum, MD, Senior Vice President of Research at Corvus Pharmaceuticals (Nasdaq: CRVS), was presented with the Distinguished Service Award by the American College of Rheumatology (ACR) at its annual meeting in Philadelphia on November 12, 2022. Dr. Rosenbaum received the ACR’s second highest honor, for his outstanding contributions to rheumatology and care of patients. Founded in 1934, the ACR is a not-for-profit, professional ass

Yahoo | November 14, 2022

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2022 Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (NASDAQ:NASDAQ:CRVS) Q3 2022 Earnings Conference Call November 03, 2022 04:30 PM ET Company Participants Zack Kubow - Investor Relations-Real Chemistry Leiv Lea…

Seeking Alpha | November 6, 2022

Read More 'CRVS' Stories Here

CRVS Price Returns

1-mo 0.15%
3-mo 1.27%
6-mo -1.15%
1-year -53.01%
3-year -83.52%
5-year -89.45%
YTD 1.18%
2022 -64.73%
2021 -32.30%
2020 -34.56%
2019 48.23%
2018 -64.58%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6814 seconds.